Navigation Links
Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
Date:4/20/2011

CAMBRIDGE, Mass., April 20, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling downstream signaling, including the phosphatidylinositol 3-kinase (PI3K) pathway, and preventing tumor proliferation. In this study, Merrimack is evaluating whether MM-111 could be safely added to standard therapies used to treat HER2 positive cancers. The study could also provide preliminary evidence of activity in patients with advanced/metastatic HER2 positive disease, an area of high unmet medical need for which there are limited treatment options.

"HER2 positive cancers are historically more aggressive and carry a poorer prognosis than other types of solid tumors," says Clet Niyikiza, Ph.D., Executive Vice President of Development, Merrimack Pharmaceuticals. "Patients with HER2 positive metastatic cancer eventually progress or are intolerant of current approved regimens. Close to half of the patients treated with such regimens fail to respond."

The Phase 1 study will evaluate the human safety and pharmacokinetics of MM-111 when administered in combination with either 1) cisplatin, capecitabine, and trastuzumab; 2) lapatinib and trastuzumab; or 3) paclitaxel and trastuzumab in patients with HER2 positive solid tumors. The study is being run in collaboration with US Oncology, a leading integrated oncology company that is affiliated with more than 1,400 physicians nationwide.

"Because ErbB3 activation has been indicated as a cause of resistance to current HER2 targeted treatments and chemotherapies, we pl
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
2. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
3. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
7. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
11. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...  Decision Resources, one of the world,s leading ... issues, announces that its Market Access Tracker service ... East and Africa ... opportunities to gaining and maintaining favorable market access ... The countries covered by Market Access Tracker make ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... Gilead Sciences, Inc. (NASDAQ: GILD ), Health Management ... (NASDAQ: IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ... readers may access these reports free of charge - including ... the links below. Gilead Sciences, Inc. Research Report ...
(Date:6/18/2013)... 18, 2013  Pro football player and 2012 most ... family expert Jo Frost have potentially life-threatening ... the fully integrated specialty pharmaceutical business of Mylan Inc. ... this significant health problem. In recognition of the 25 ... Administration (FDA) approval of EpiPen ® (epinephrine) Auto-Injector, ...
Breaking Medicine Technology:Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8
(Date:6/19/2013)... 19, 2013 The website HealthNewsWires.com has ... resistance, its harmful effects and tips to manage and ... video from HealthNewsWires.com, the author defines insulin resistance ... efficiently remove and process glucose from the bloodstream. ... by all cells, organs and systems of the body ...
(Date:6/19/2013)... Audibel Hearing Center is pleased ... patients, the A2 with Multiflex Tinnitus Technology. Tinnitus ... in the ears. Although bothersome, tinnitus usually isn’t ... , Using their patent-pending Multiflex Tinnitus Technology, the ... sound stimulus that resonates through the patient’s ear. ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Anant Goel, CEO at RKNet Studios ... industrial revolution began in Britain in the late 18th century, ... was born. The second industrial revolution came in the early ... and ushered in the age of mass production. Now a ... is going digital and this could change not just business, ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 On 31 ... the concern about involuntarily detaining patients, a proposal put ... holistic addiction and mental health service provider , The ... apprehension about the suggestion. The centre’s Director and ... assumes those suffering from mental health issues have no ...
Breaking Medicine News(10 mins):Health News:Effects of Insulin Resistance and How to Increase Insulin Sensitivity Published in New Video by Health News Wire 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 3Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 4Health News:Involuntary Detention Proposal Dehumanizing, Says Holistic Mental Health Service Provider The Australian Addiction And Trauma Treatment Centre 2Health News:Involuntary Detention Proposal Dehumanizing, Says Holistic Mental Health Service Provider The Australian Addiction And Trauma Treatment Centre 3
... ... tomography examinations underscore the important role that competent, educated CT technologists play in ... , ... Albuquerque, NM (Vocus) December 16, 2009 -- Two recent studies examining radiation doses ...
... , VIRGINIA BEACH, Va., Dec. 17, ... 12 Hampton Roads-area non-profit organizations at its first ,Breakfast ... mistress of ceremonies was local television personality, Barbara Ciara, ... breakfast keynote speaker was world-renowned ,champion, and four-time heavyweight ...
... Dec. 17 Motionsoft, Inc. announced today that it has ... Standards (DSS) certification, making it one of only a handful ... has been granted PCI compliance. , The PCI Standard is ... major credit card companies (Visa International, MasterCard Worldwide, American Express, ...
... , MIAMI, Dec. 17 ... , today announced that it has issued its financial ... financials are being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is ...
... ... Inc. (OTC Bulletin Board: VHGI) confirmed today that VHGI Gold ... for a key advisory board position to assist with evaluating ... a decision for the role and hopes to make an ...
... and glutathione S-transferase T1 (GSTT1) null genotypes have been ... regarding the association between GSTM1 and GSTT1 null genotypes ... However, the majority of previous reports are limited by ... GSTM1/GSTT1 null genotype with the risk of GC and ...
Cached Medicine News:Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 4Health News:The Amerigroup Foundation 'Breakfast of Champions' Honors Community Leaders with Boxing Champion Evander Holyfield 2Health News:The Amerigroup Foundation 'Breakfast of Champions' Honors Community Leaders with Boxing Champion Evander Holyfield 3Health News:Motionsoft Completes PCI Compliance Certification 2Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 2Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 3Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 4
... contains primers and a FAM-labeled probe that ... (RSV). In addition, this ASR contains primers ... sample processing control. This ASR requires an ... Red reporter dyes such as the Cepheid ...
... contains primers and a FAM-labeled probe that is ... the Staphylococcus protein A gene. In addition, this ... DNA for an internal control sequence. This ASR ... Texas Red reporter dyes such as the Cepheid ...
Clot-based Assay for Anti-FXa and/or Anti-Iia Therapies...
Reptilase-Time from Bothrops atrox...
Medicine Products: